ERBB2 and breast carcinoma: Similarly, BELLE-3, a randomized, double-blind, placebo-controlled, multicenter, phase III study, evaluated the safety and efficacy of buparlisib plus fulvestrant in patients with advanced HR+ HER2 negative (HER2−) breast cancer who were pretreated with endocrine therapy and mTOR inhibition [28].